The following materials are valid only for users based in the United States or subjected to the US FDA regulations on in-vitro diagnostics (IVD) devices. Users based in countries other than the US may refer to MTS™ materials listed at www.liofilchem.com/MTS
| e-IFU | latest revision | 510(k) Substantial Equivalence Determination Decision Summary |
|---|---|---|
| MTS™ Ceftobiprole | rev.0 - 30/01/2025 |  |
| MTS™ Piperacillin-tazobactam | rev.2 - 19/09/2023 | |
| MTS™ Lefamulin | rev.0 - 06/04/2020 | |
| MTS™ Ampicillin-sulbactam | rev.0 - 06/12/2019 | |
| MTS™ Imipenem | rev.1 - 19/04/2022 | |
| MTS™ Imipenem-relebactam | rev.2 - 19/04/2022 | |
| MTS™ Doxycycline | rev.1 - 19/04/2022 | |
| MTS™ Gentamicin | rev.1 - 19/04/2022 | |
| MTS™ Ciprofloxacin | rev.2 - 19/04/2022 | |
| MTS™ Levofloxacin | rev.2 - 19/04/2022 | |
| MTS™ Tetracycline | rev.0.1 - 01/09/2020 | |
| MTS™ Omadacycline | rev.2 - 19/04/2022 | |
| MTS™ Eravacycline | rev.0 - 02/11/2018 | |
| MTS™ Penicillin G | rev.1 - 19/04/2022 | |
| MTS™ Plazomicin | rev.0 - 31/07/2018 | |
| MTS™ Delafloxacin | rev.1 - 29/06/2018 | |
| MTS™ Azithromycin | rev.0 - 29/05/2018 | |
| MTS™ Meropenem | rev.3 - 19/04/2022 | |
| MTS™ Tedizolid | rev.2 - 23/10/2017 | |
| MTS™ Erythromycin | rev.0.1 - 31/01/2020 | |
| MTS™ Clindamycin | rev.1 - 19/04/2022 | |
| MTS™ Meropenem-vaborbactam | rev.2 - 19/04/2022 | |
| MTS™ Ceftazidime-avibactam | rev.1 - 19/04/2022 | |
| MTS™ Linezolid | rev.0.1 - 11/05/2018 | |
| MTS™ Telavancin | rev.1 - 30/08/2017 | |
| MTS™ Ceftazidime | rev.2 - 19/04/2022 | |
| MTS™ Ceftolozane-tazobactam | rev.4 - 19/04/2022 | |
| MTS™ Dalbavancin | rev.2 - 19/04/2022 | |
| MTS™ Vancomycin | rev.3 - 19/04/2022 | |
| Lot specific e-IFU |